title: Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone.
authors: Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors: Edward
authors: E
authors: Renaudon-Smith
authors: John G
authors: JG
authors: Gribben
authors: Samir G
authors: SG
authors: Agrawal
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074323:Alemtuzumab; D008775:Methylprednisolone